Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page
- Check7 days agoChange DetectedAdded a site revision note: v3.5.0 and removed the previous revision note: v3.4.3.SummaryDifference0.1%

- Check14 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3. No study data or essential content appears to be affected.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check43 days agoChange DetectedRevision: v3.4.2 was added; the previous 'Notice about government funding' and 'Revision: v3.4.1' items were removed.SummaryDifference0.4%

- Check50 days agoChange DetectedA site-wide notice about a lapse in government funding was added, informing users that information may not be up to date and directing them to opm.gov for updates. The page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check57 days agoChange DetectedThis update adds a glossary option and standardizes capitalization of metadata labels (e.g., 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data') along with a new Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check64 days agoChange DetectedRevision update from v3.3.3 to v3.3.4; no visible changes to study content or page functionality detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.